<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02427165</url>
  </required_header>
  <id_info>
    <org_study_id>RPL554-008-2014</org_study_id>
    <nct_id>NCT02427165</nct_id>
  </id_info>
  <brief_title>Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients</brief_title>
  <official_title>A Phase II, Randomised, Double Blind, Placebo Controlled, Seven Way Crossover Study to Assess the Effect of Single Doses of RPL554 Compared to Salbutamol and Placebo Administered by Nebuliser on Lung Function of Patients With Chronic Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verona Pharma plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verona Pharma plc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The number of people with of asthma and allergy is still increasing and a large number of
      patients still do not have their asthma well controlled. There is therefore a need for new
      asthma treatments that work well and have less side effects. The study compares a new
      experimental drug RPL554 with a marketed asthma drug (salbutamol) and placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A seven way crossover study to investigate the pharmacodynamics, pharmacokinetics, safety and
      tolerability of inhaled RPL554 compared to salbutamol and placebo in patients with mild to
      moderate chronic asthma.

      Salbutamol is a marketed beta-2 agonist typically used to treat bronchospasm (due to any
      cause, allergen asthma or exercise-induced), as well as chronic obstructive pulmonary disease
      but has associated dose-related systemic side effects.

      RPL554 is a dual PDE3 and PDE4 inhibitor that has bronchodilatory and anti-inflammatory
      actions and also the potential to stimulate increases in mucociliary clearance via its proven
      ability to activate CFTR. Four different doses of RPL554 will be compared with placebo and a
      two doses of salbutamol as benchmarks for bronchodilation and systemic side effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spirometry</measure>
    <time_frame>12 hours</time_frame>
    <description>FEV1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spirometry</measure>
    <time_frame>4, 6 and 8 hours</time_frame>
    <description>FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic pharmacodynamic effect on blood pressure</measure>
    <time_frame>4 hours</time_frame>
    <description>Supine blood pressure in the 4 hours after nebulisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic pharmacodynamic effect on pulse rate</measure>
    <time_frame>4 hours</time_frame>
    <description>Supine Pulse rate in the 4 hours after nebulisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic pharmacodynamic effect on ECG heart rate</measure>
    <time_frame>4 hours</time_frame>
    <description>ECG heart rate in the 4 hours after nebulisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs (Supine pulse rate)</measure>
    <time_frame>12 hours</time_frame>
    <description>Supine pulse rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs (Supine blood pressure)</measure>
    <time_frame>12 hours</time_frame>
    <description>Supine systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>12 hours</time_frame>
    <description>12-lead ECG parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC)</measure>
    <time_frame>12 hours</time_frame>
    <description>RPL554 AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax)</measure>
    <time_frame>12 hours</time_frame>
    <description>RPL554 Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (tmax)</measure>
    <time_frame>12 hours</time_frame>
    <description>RPL554 tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (half life)</measure>
    <time_frame>12 hours</time_frame>
    <description>RPL554 half life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (MRT)</measure>
    <time_frame>12 hours</time_frame>
    <description>RPL554 MRT</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of nebulised placebo solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RPL554 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.4 mg single dose nebulised RPL554</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RPL554 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg single dose nebulised RPL554</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RPL554 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg single dose nebulised RPL554</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RPL554 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 mg single dose nebulised RPL554</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salbutamol Dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5 mg single dose nebulised salbutamol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salbutamol Dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7.5 mg single dose nebulised salbutamol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPL554</intervention_name>
    <description>A dual PDE3 and PDE4 inhibitor</description>
    <arm_group_label>RPL554 Dose 1</arm_group_label>
    <arm_group_label>RPL554 Dose 2</arm_group_label>
    <arm_group_label>RPL554 Dose 3</arm_group_label>
    <arm_group_label>RPL554 Dose 4</arm_group_label>
    <other_name>VMX554</other_name>
    <other_name>VRP554</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol</intervention_name>
    <description>a beta-2 receptor agonist</description>
    <arm_group_label>Salbutamol Dose 1</arm_group_label>
    <arm_group_label>Salbutamol Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>RPL554 placebo containing no active ingredients</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provided written informed consent

          -  Males agree not to donate sperm and either be abstinent or use adequate contraception.
             Females to be post-menopausal or surgically sterile

          -  Non-smoker or ex-smoker &gt;6 months

          -  Diagnosed asthma for at least 6 months

          -  Pre-bronchodilator FEV1 ≥60% and ≤90% of predicted normal value and ≥1.5 L at
             screening

          -  Increase in FEV1 of 15% within 30 minutes after a 2.5mg dose of nebulised salbutamol

          -  Systolic blood pressure 90 to 145 mmHg, diastolic blood pressure 50 to 90 mmHg and
             heart rate 45 to 80 beats per minute (bpm) after resting for 5 minutes in a supine
             position (average from two measurements)

          -  Capable of withdrawing from LABAs, LAMAs and SAMAs before screening and during study
             and SABAs before screening and for 8 hours before each dose

        Exclusion Criteria:

          -  Asthma exacerbation in the last 3 months

          -  Any prior life threatening episode of asthma (intensive care admission)

          -  Any clinically significant disease or disorder or clinically relevant screening result

          -  QTcF interval &gt;450 ms or QT interval &gt;500 ms or other abnormality in ECG

          -  History of ischemic heart disease or heart failure. History of recurrent or current
             clinically significant arrhythmia or ECG abnormality as judged by the investigator

          -  Treatment with systemic glucocorticosteroids within 30 days before screening

          -  A suspected/manifested infection according to WHO risk classification 2, 3 or 4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lief Bjermer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skane University Hospital, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johnston Stewart</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion, Northern Ireland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>April 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2015</study_first_posted>
  <last_update_submitted>September 8, 2016</last_update_submitted>
  <last_update_submitted_qc>September 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

